Crucell to start rabies Phase I antibody cocktail clinical study in India |
|
|
|
Published
:
Wed, 04 Apr 2007 07:40
|
AMSTERDAM (AFX) - Crucell NV said its rabies monoclonal antibody product has entered a Phase I clinical study in India, four months after launching a similar study in the US.The second Phase I study is closely linked to the initial Phase I study that is currently being performed in the US.Both studies are conducted under US Food and Drug Administration authority and the Indian Phase I study gained approval upon review by the Drug Controller-General of India (DCGI).The clinical trial will be a randomised, double-blind, placebo-controlled study in 44 healthy volunteers that will test the antibody product alone in a dose escalation as well as in combination with rabies vaccine.The study, funded by Crucell, will be conducted through a clinical research organisation in Mumbai, India.aaron.gray-block@thomson.comagb/jagCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Bentley OK to start India Nasulin study 